Small molecule ROCK2 inhibitors, such as Netarsudil and Ripasudil, are used in therapeutic settings to reduce IOP and treat glaucoma by reducing the resistance to AH outflow by relaxing the trabecular meshwork smooth muscle [15,16]. This evidence concerns the gene ROCK2 and glaucoma.